

Special Issue

Molecular Mechanisms of Anti-Cancer Drugs Action

Message from the Guest Editor

In recent decades, the most important clinical improvements in anticancer drugs have occurred with the debut of treatments with novel mechanisms of action. Researchers have also learned that the microenvironment in which different cancers start, grow, and thrive are not always the same. Tumor heterogeneity is the main cause of drug resistance leading to therapeutic failure. Because drug resistance occurs through different mechanisms due to genetic, epigenetic, and phenotypic heterogeneity, understanding the mechanisms of anticancer drug, as well as the design and development of improved or novel targeted drugs with unique modes of action, is urgently needed. This Special Issue will highlight recent advances and strategies in the mechanisms of action of anticancer drugs: from in silico design to synthesis to biological activity. It will cover the role of (potential) drugs in overcoming drug resistance and major limitations of traditional treatments. Thereby, we are pleased to invite you to submit research articles, short communications, and systematic reviews that will bring significant contributions to this topic.

Guest Editor

Dr. Barbara Pucelik

Małopolska Centre of Biotechnology, Jagiellonian University,
Gronostajowa 7A, 30-387 Krakow, Poland

Deadline for manuscript submissions

closed (30 May 2024)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/151731

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)